Conclusions & Recommendations
TEC 24
24.12.2 - Mozambique
2021
Heading 2
Africa - Central/Southern
TEC notes the security challenges in Cabo Delgado and the threat they pose to elimination in Mozambique. TEC recommends that ITI work with countries to document population disruptions and the potential impact of IDPs/refugees on progress towards elimination, and to propose ways to assist national decision-making on how to account for changing population numbers for future MDAs and/or surveys.
Mozambique
Conclusion/Recommendation:
The national program visited Cabo Delgado in March and is exploring the possibility of completing impact surveys in four southern districts in 2022. Additionally, IDPs from Cabo Delgado were included in the 2021 MDAs in Nampula and additional Zithromax® has also been allocated for their inclusion in the 2022 MDAs.
insecurity, special populations
TEC 24
24.12.1 - Mozambique
2021
Heading 2
Africa - Central/Southern
TEC recommends that the MOH and partners consider collecting infection data in districts with TF1-9 just above 5% at TIS and TSS in several districts. This may be a sign of lagging TF rather than a need for additional MDA or recrudescence, and infection data would provide a more complete picture of trachoma in those districts.
Mozambique
Conclusion/Recommendation:
This recommendation has been shared with the country. Following the TEC guidance that arose from the December 2021 WHO Informal Consultation, the national program has proposed a modified treatment and monitoring strategy.
alternative indicators (Ct, serology), end game, research
TEC 24
24.11.2 - DRC
2021
Heading 2
Africa - Central/Southern
TEC encourages the MOH to access available funding from ESPEN for trachoma activities where there are gaps and encourages other donors to further support the MOH in achieving elimination.
DRC
Conclusion/Recommendation:
This recommendation has been shared with the country
funding
TEC 24
24.11.1 - DRC
2021
Heading 2
Africa - Central/Southern
TEC recognizes that DRC has the second highest population at-risk of trachoma in the world and is at risk of losing momentum of the existing progress, putting more people at risk of trachoma if adequate funding and technical support cannot be identified.
DRC
Conclusion/Recommendation:
No action required
funding
TEC 24
24.10.1 - Peru
2021
Heading 2
Americas
TEC notes that despite several consecutive years of approving the Zithromax® request, MDA has not yet started. TEC recommends that ITI continue to monitor this situation closely and follow-up to ensure the MOU is signed.
Peru
Conclusion/Recommendation:
ITI presented on these challenges in September 2021 during the PAHO Americas meetings and continues to discuss the challenges with PAHO and the MOH in Peru. ITI and PAHO hope that an agreement to ship Zithromax® via PAHO will replace the highly bureaucratic MOU process, which has been stalled for several years.
recommendations for ITI management
TEC 24
24.1.5 - General Recommendations
2021
Heading 2
add more details regarding requests for Zithromax® post-TT surgery (funders and implementing partners)
Conclusion/Recommendation:
This information is being collected in the 2023 Zithromax® for TT-Surgery application form.
TEC meeting management, trichiasis
TEC 24
24.1.4 - General Recommendations
2021
Heading 2
add the definition of coverage to the ‘cheat sheet’
Conclusion/Recommendation:
The definition of Zithromax® coverage has been edited and is included on the TEC cheat sheet
TEC meeting management, coverage
TEC 24
24.1.3 - General Recommendations
2021
Heading 2
include regional prevalence maps in the TEC book, behind each regional tab, so that the cross-border situation can be taken into account when reviewing applications
Conclusion/Recommendation:
These regional prevalence maps will be included beginning TEC 27
TEC meeting management, COVID
TEC 24
24.1.2 - General Recommendations
2021
Heading 2
include Zithromax® requests for research as rows on the applications (e.g., REACH; Stronger SAFE; KETFO)
Conclusion/Recommendation:
A research request form has been added to the surgery request form to track these requests with greater detail
TEC meeting management, research
TEC 24
24.1.1 - General Recommendations
2021
Heading 2
Include district-level data on infection, where available, to provide a more complete picture of trachoma in these areas (using publicly-available data and/or with permission from the MOH/researchers)
Conclusion/Recommendation:
A new column to track this has been added to the TEMFs and publicly-available data is included in the Notes column on the Zithromax® Applications
alternative indicators (Ct, serology), TEC meeting management